<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472326</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-442-4148</org_study_id>
    <nct_id>NCT03472326</nct_id>
  </id_info>
  <brief_title>Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus, Followed by Continued Treatment With a GS-9131+Bictegravir+Darunavir+Ritonavir Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the short-term antiviral potency of a
      regimen containing GS-9131 at 30 mg, 60 mg, and 90 mg, compared to placebo-to-match (PTM)
      GS-9131, each administered once daily with the existing failing antiretroviral therapy (ART)
      regimen.

      This is a two-part study. Part 1 consists of two cohorts: a Sentinel Cohort followed by a
      Randomized Cohort. Eligible participants from Part 1 will proceed to Part 2 followed by an
      optional open-label extension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Proportion of Participants With Plasma HIV-1 RNA Decrease From Baseline Exceeding 0.5 log₁₀ at Day 11 in the Randomized Cohort</measure>
    <time_frame>Day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in Plasma log₁₀ HIV-1 RNA (copies/mL) at Day 11 in Both Cohorts</measure>
    <time_frame>Part 1 Baseline to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Proportion of Participants With Plasma HIV-1 RNA &lt; 50 copies/mL as Defined by the US FDA Snapshot Algorithm at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Part 2 Baseline in Plasma log₁₀ HIV-1 RNA (copies/mL) at Week 24</measure>
    <time_frame>Part 2 Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Part 2 Baseline in CD4+ cell count (cells/μL) at Week 24</measure>
    <time_frame>Part 2 Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Treatment-Emergent Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI) Mutations at the time of Virologic Failure</measure>
    <time_frame>Part 1 Baseline to Part 2 Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Treatment-Emergent Protease Inhibitor (PI) Mutations at the time of Virologic Failure</measure>
    <time_frame>Part 1 Baseline to Part 2 Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Treatment-Emergent Integrase Strand-Transfer Inhibitor (INSTI) Mutations at the time of Virologic Failure</measure>
    <time_frame>Part 1 Baseline to Part 2 Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Part 1: Sentinel Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment experienced participants will receive open-label GS-9131 60 mg (2 x 30 mg tablets) once daily + current failing ART regimen for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm A: GS-9131 30 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9131 30 mg (1 x 30 mg tablet) once daily + current failing ART regimen for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm B: GS-9131 60 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9131 60 mg (2 x 30 mg tablets) once daily + current failing ART regimen for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm C: GS-9131 90 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9131 90 mg (3 x 30 mg tablets) once daily + current failing ART regimen for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm D: GS-9131 Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9131 placebo + current failing ART regimen for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GS-9131 30 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Treatment Arms A and D in Part 1 will receive GS-9131 30 mg (1 x 30 mg tablet) + bictegravir (BIC) + darunavir (DRV)+ritonavir (RTV) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Sentinel Cohort, and, Treatment Arms B and C in Part 1 will receive GS-9131 60 mg (2 x 30 mg tablets) + BIC + DRV+RTV for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 2 may have the option to receive open-label GS-9131 + BIC + DRV+RTV for an additional 24 weeks or until the product becomes accessible to participants through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9131</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Part 1: Sentinel Cohort</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm A: GS-9131 30 mg)</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm B: GS-9131 60 mg)</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm C: GS-9131 90 mg)</arm_group_label>
    <arm_group_label>Part 2: GS-9131 30 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-to-match (PTM) GS-9131 tablets</description>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm D: GS-9131 Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIC</intervention_name>
    <description>30 mg tablet(s) administered orally once daily</description>
    <arm_group_label>Part 2: GS-9131 30 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV</intervention_name>
    <description>800 mg tablet(s) administered orally once daily</description>
    <arm_group_label>Part 2: GS-9131 30 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
    <other_name>Prezista®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>100 mg tablet(s) administered orally once daily</description>
    <arm_group_label>Part 2: GS-9131 30 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV+RTV Regimen</arm_group_label>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
    <other_name>Norvir®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART regimen</intervention_name>
    <description>ART regimen may consist of the current failing antiretroviral agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)</description>
    <arm_group_label>Part 1: Sentinel Cohort</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm A: GS-9131 30 mg)</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm B: GS-9131 60 mg)</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm C: GS-9131 90 mg)</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm D: GS-9131 Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Plasma HIV-1 RNA ≥ 500 copies/mL at Screening Visit

          -  Currently taking a failing antiretroviral (ARV) regimen that contains 2 NRTIs and a
             non-NRTI (NNRTI)

          -  No prior or current ARV regimens containing integrase inhibitor (INSTI) or protease
             inhibitor (PI)

          -  Screening genotype must show at least the protocol defined resistance mutation profile

        Key Exclusion Criteria:

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to Day 1

          -  Participation in any other clinical trial, including observational studies, without
             prior approval from the sponsor is prohibited while participating in this trial

          -  Use of an investigational drug other than the study drug

          -  Adults with chronic hepatitis B virus (HBV) infection are not permitted to participate

          -  Active tuberculosis infection

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Joint Clinical Research Centre</name>
      <address>
        <city>Kampala</city>
        <zip>10005</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

